Acromegaly Therapeutics Market Report 2025 (Global Edition)

Global Acromegaly Therapeutics Market Report 2024 Market Size Split by Type (Octreotide, Pasireotide, Lanreotide, Pegvisomant), by Application (Hospital, Pharmacy), by Treatment Type (Medical therapy,...

Acromegaly Therapeutics Market Report Description

We have various report editions of Acromegaly Therapeutics Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Acromegaly Therapeutics Market Insights Video

Competitive Landscape of the Acromegaly Therapeutics Market

The competitive landscape of the Acromegaly Therapeutics Market features key players such as Novartis, Ipsen, and Pfizer, which dominate with established therapies like somatostatin analogs and growth hormone receptor antagonists. These companies are actively engaged in R&D to introduce innovative treatments with improved efficacy and safety profiles. Emerging players and biotechnology firms are also entering the market, contributing to a dynamic environment characterized by ongoing advancements and increased competition for market share.

In Mar 2024, Crinetics Pharmaceuticals, Inc. reported positive topline findings from PATHFNDR-2, the second of two Phase 3 studies assessing the efficacy and safety of paltusotine, an oral, once-daily experimental therapy for acromegaly. (Source: https://crinetics.com/crinetics-once-daily-oral-paltusotine-achieved-the-primary-and-all-secondary-endpoints-in-the-phase-3-pathfndr-2-study-in-acromegaly-patients/ )

Top Companies Market Share in Acromegaly Therapeutics Industry: (In no particular order of Rank)

• ADVANZ PHARMA
• Amryt Pharma Plc
• Chiasma
• Inc
• Cipla
• Crinetics Pharmaceuticals Inc
• Dauntless Pharmaceuticals
• Eli Lilly and Company
• Ipsen SA
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Acromegaly Therapeutics Market

Which Region Dominates the Acromegaly Therapeutics Market in 2024?

According to Cognitive Market Research, North America holds the dominant position in the Acromegaly Therapeutics Market due to its advanced healthcare infrastructure, high prevalence of acromegaly, and significant investments in pharmaceutical research and development. The region benefits from a robust healthcare system, which supports the early diagnosis and effective management of acromegaly. Key pharmaceutical companies in North America are at the forefront of developing and introducing innovative therapies, enhancing treatment options available to patients. The presence of well-established medical institutions and a high level of awareness about the disease further contribute to North America's leading market share. This dominance is bolstered by substantial market investment and ongoing advancements in therapeutic technologies.

Which Region is Expanding at the Fastest CAGR?

The Asia-Pacific region is expanding at the fastest CAGR in the Acromegaly Therapeutics Market. This rapid growth is driven by increasing healthcare access, rising disease awareness, and a growing patient population within emerging economies. Expanding healthcare infrastructure and improving medical facilities contribute to the region's dynamic market expansion. Pharmaceutical companies are increasingly focusing on this region due to its large market potential and evolving healthcare landscape. The growing adoption of advanced treatment options and investments in local R&D further accelerate the market's growth trajectory in Asia-Pacific. Rising disposable incomes and increased government spending on healthcare are also key factors fueling this rapid expansion.

 

The current report Scope analyzes Acromegaly Therapeutics Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Acromegaly Therapeutics Market

According to Cognitive Market Research, the global Acromegaly Therapeutics Market size was estimated at USD 2515.2 Million, out of which North America held the major market of more than 40% of the global revenue with a market size of USD 1006.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.2% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Acromegaly Therapeutics Market with a market size of USD 793.80 million in 2024 and is projected to grow at a CAGR of 4.0% during the forecast period. Advanced healthcare infrastructure and high research investment drive market growth.
• The Canada Acromegaly Therapeutics Market had a market share of USD 120.73 million in 2024 and is projected to grow at a CAGR of 5.0% during the forecast period. Strong healthcare system and increasing disease awareness boost market expansion.
• The Mexico Acromegaly Therapeutics Market is projected to witness growth at a CAGR of 4.7% during the forecast period, with a market size of USD 91.55 million in 2024.

Europe Acromegaly Therapeutics Market

According to Cognitive Market Research, the global Acromegaly Therapeutics Market size was estimated at USD 2515.2 Million, out of which Europe held the market of more than 30% of the global revenue with a market size of USD 754.56 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.5% from 2024 to 2031.

• The United Kingdom Acromegaly Therapeutics Market had a market share of USD 126.77 million in 2024 and is projected to grow at a CAGR of 5.3% during the forecast period. Comprehensive medical services and ongoing research support market growth.
• The France Acromegaly Therapeutics Market is projected to witness growth at a CAGR of 3.7% during the forecast period, with a market size of USD 69.42 million in 2024.
• According to Cognitive Market Research, the German Acromegaly Therapeutics Market size was valued at USD 149.40 million in 2024 and is projected to grow at a CAGR of 4.7% during the forecast period. Leading pharmaceutical research and robust healthcare services enhance market dynamics.
• The Italy Decorative Laminates Market is projected to witness growth at a CAGR of 3.9% during the forecast period, with a market size of USD 64.89 million in 2024.
• The Russia Decorative Laminates Market is projected to witness growth at a CAGR of 3.5% during the forecast period, with a market size of USD 116.96 million in 2024.
• The Spain Decorative Laminates Market is projected to witness growth at a CAGR of 3.6% during the forecast period, with a market size of USD 61.87 million in 2024.
• The Luxembourg Decorative Laminates Market is projected to witness growth at a CAGR of 4.6% during the forecast period, with a market size of USD 23.39 million in 2024.
• The Portugal Decorative Laminates Market is projected to witness growth at a CAGR of 4.3% during the forecast period, with a market size of USD 15.85 million in 2024.
• The Greece Decorative Laminates Market is projected to witness growth at a CAGR of 4.8% during the forecast period, with a market size of USD 9.05 million in 2024.
• The Rest of Europe Decorative Laminates Market is projected to witness growth at a CAGR of 3.2% during the forecast period, with a market size of USD 116.96 million in 2024.

Asia Pacific Acromegaly Therapeutics Market

According to Cognitive Market Research, the global Acromegaly Therapeutics Market size was estimated at USD 2515.2 Million, out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 578.50 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.0% from 2024 to 2031.

• According to Cognitive Market Research, the China Acromegaly Therapeutics Market size was valued at USD 260.32 million in 2024 and is projected to grow at a CAGR of 7.5% during the forecast period. Rapid economic development and expanding healthcare access fuel market growth.
• The Japan Decorative Laminates Market is projected to witness growth at a CAGR of 6.5% during the forecast period, with a market size of USD 79.83 million in 2024.
• The India Acromegaly Therapeutics Market had a market share of USD 69.42 million in 2024 and is projected to grow at a CAGR of 9.8% during the forecast period. Rising healthcare investments and growing disease awareness drive market expansion.
• The South Korea Decorative Laminates Market is projected to witness growth at a CAGR of 7.1% during the forecast period, with a market size of USD 57.85 million in 2024.
• The Australia Decorative Laminates Market is projected to witness growth at a CAGR of 7.7% during the forecast period, with a market size of USD 30.08 million in 2024.
• The South East Asia Decorative Laminates Market is projected to witness growth at a CAGR of 9.0% during the forecast period, with a market size of USD 39.92 million in 2024.
• The Rest of APAC Decorative Laminates Market is projected to witness growth at a CAGR of 7.8% during the forecast period, with a market size of USD 41.07 million in 2024.

South America Acromegaly Therapeutics Market

According to Cognitive Market Research, the global Acromegaly Therapeutics Market size was estimated at USD 2515.2 Million, out of which the Latin America market has more than 5% of the global revenue with a market size of USD 125.76 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031. .

• According to Cognitive Market Research, the Brazil Acromegaly Therapeutics Market size was valued at USD 53.83 million in 2024 and is projected to grow at a CAGR of 6.0% during the forecast period. Improving healthcare infrastructure and increased patient education support market growth.
• Argentina's Acromegaly Therapeutics Market had a market share of USD 21.13 million in 2024 and is projected to grow at a CAGR of 6.3% during the forecast period. Advancements in healthcare services and rising awareness contribute to market expansion.
• The Colombia Decorative Laminates Market is projected to witness growth at a CAGR of 5.2% during the forecast period, with a market size of USD 11.19 million in 2024.
• The Peru Decorative Laminates Market is projected to witness growth at a CAGR of 5.6% during the forecast period, with a market size of USD 10.31 million in 2024.
• The Chile Decorative Laminates Market is projected to witness growth at a CAGR of 5.7% during the forecast period, with a market size of USD 9.05 million in 2024.
• The Rest of LATAM Decorative Laminates Market is projected to witness growth at a CAGR of 4.5% during the forecast period, with a market size of USD 20.25 million in 2024.

Middle East and Africa Acromegaly Therapeutics Market

According to Cognitive Market Research, the global Acromegaly Therapeutics Market size was estimated at USD 2515.2 Million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 50.30 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.7% from 2024 to 2031.

• The GCC Countries Acromegaly Therapeutics Market is projected to witness growth at a CAGR of 6.5% during the forecast period, with a market size of USD 21.53 million in 2024. Expanding healthcare facilities and rising interest in rare disease treatments drive growth.
• The Egypt Decorative Laminates Market is projected to witness growth at a CAGR of 6.0% during the forecast period, with a market size of USD 5.28 million in 2024.
• The South Africa Acromegaly Therapeutics Market is projected to witness growth at a CAGR of 6.7% during the forecast period, with a market size of USD 7.95 million in 2024. Enhanced healthcare infrastructure and growing patient awareness boost market dynamics.
• The Turkey Decorative Laminates Market is projected to witness growth at a CAGR of 5.2% during the forecast period, with a market size of USD 4.33 million in 2024.
• The Nigeria Decorative Laminates Market is projected to witness growth at a CAGR of 4.8% during the forecast period, with a market size of USD 5.28 million in 2024.
• The Rest of MEA Decorative Laminates Market is projected to witness growth at a CAGR of 4.7% during the forecast period, with a market size of USD 5.94 million in 2024.

Acromegaly Therapeutics Market Analysis

Global Acromegaly Therapeutics Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Acromegaly Therapeutics Industry growth. Acromegaly Therapeutics market has been segmented with the help of its Type, Application Treatment Type, and others. Acromegaly Therapeutics market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.

Acromegaly Therapeutics Market Type Segment Analysis

According to Cognitive Market Research, Somatostatin analogs represent the largest segment in the Acromegaly Therapeutics Market. This dominance stems from their established efficacy in controlling excessive growth hormone production and managing acromegaly symptoms. Key drugs, such as octreotide and lanreotide, are widely used due to their proven track record and comprehensive clinical data supporting their use. Their role as first-line therapy in the management of acromegaly, combined with their broad acceptance among healthcare professionals, solidifies their leading position. The market's reliance on these well-established therapies reflects their critical role in treatment protocols and their consistent demand across various healthcare settings.

Growth hormone receptor antagonists are the fastest-growing segment within the Acromegaly Therapeutics Market. Their rapid expansion is driven by the innovative approach of blocking growth hormone effects at the receptor level, offering a new therapeutic pathway for patients. Pegvisomant, a prominent drug in this category, has demonstrated significant potential in cases where traditional therapies may be insufficient. The increasing adoption of these antagonists is fueled by their ability to provide effective management of acromegaly with a distinct mechanism of action. Market growth in this segment is further propelled by ongoing research and the development of new formulations aimed at enhancing patient outcomes.

Acromegaly Therapeutics Market Share (%) by Type in 2019-2031

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Acromegaly Therapeutics Industry. Request a Free Sample PDF!

Acromegaly Therapeutics Market Application Segment Analysis

According to Cognitive Market Research, The hospital segment dominates the Acromegaly Therapeutics Market, driven by its comprehensive approach to diagnosing and managing complex cases. Hospitals offer advanced diagnostic tools, specialized care, and a range of treatment options, including surgery and sophisticated medical therapies. The extensive infrastructure, including specialized medical teams and equipment, supports the effective management of acromegaly. This segment benefits from the high volume of patients requiring intensive treatment and monitoring. With hospitals being the primary setting for the initiation and ongoing management of acromegaly therapy, this segment continues to capture the largest market share, reflecting its pivotal role in patient care and treatment delivery.

The pharmacy segment is experiencing the fastest growth within the Acromegaly Therapeutics Market. This rapid expansion is fueled by increasing patient preference for outpatient care and the convenience of obtaining medications directly from pharmacies. Pharmacies provide accessible and often more affordable options for patients, with a growing emphasis on the availability of specialized acromegaly medications. The rise in chronic disease management and self-medication trends further accelerates this segment's growth. Pharmacies also benefit from advancements in telepharmacy and improved distribution networks, making it easier for patients to access necessary therapies. This segment's dynamic expansion reflects a shift towards more accessible and patient-centric treatment solutions.

Acromegaly Therapeutics Market Share (%) by Application in 2019-2031

2019

2023

2031

The above Graph is for representation purposes only. This chart does not depict actual Market share.

To learn more about market share request the free sample pages.

Get Free Sample

Acromegaly Therapeutics Treatment Type Segment Analysis

Acromegaly Therapeutics Market Treatment Type Segment Analysis

According to Cognitive Market Research, Medical therapy, encompassing somatostatin analogs, growth hormone receptor antagonists, and dopamine agonists, represents the largest segment in the Acromegaly Therapeutics Market. Somatostatin analogs such as octreotide and lanreotide are pivotal in managing excessive growth hormone levels, controlling symptoms, and shrinking tumors. Growth hormone receptor antagonists like pegvisomant provide a targeted approach to block the action of growth hormone. This segment's prominence is underpinned by its established efficacy and broad clinical use. The extensive adoption of these therapies, coupled with ongoing advancements, solidifies medical therapy's position as the dominant segment in the market, reflecting its critical role in acromegaly management.

Combination drugs are emerging as the fastest-growing segment within the Acromegaly Therapeutics Market. These therapies integrate multiple treatment modalities to enhance efficacy and address various aspects of acromegaly management. By combining somatostatin analogs with other agents like growth hormone receptor antagonists or dopamine agonists, combination drugs offer a comprehensive approach to controlling hormone levels and alleviating symptoms. The segment’s rapid expansion is driven by the increasing need for more effective and personalized treatment regimens. The growing focus on optimizing treatment outcomes through combination therapies accelerates this segment’s growth, reflecting a shift towards more tailored and robust treatment strategies.

• Medical therapy
• Type
• Somatostatin analogs
• Growth hormone receptor antagonists (GHRA)
• Dopamine agonists
• Combination drugs
• Route of administration
• Injectable
• Oral
• Intranasal
• Surgery
• Other treatment types

Acromegaly Therapeutics Age Group Segment Analysis

Acromegaly Therapeutics Market Age Group Segment Analysis

According to Cognitive Market Research, The age group segment of 41-60 years represents the largest share in the Acromegaly Therapeutics Market. This demographic is most affected by acromegaly, as the condition often manifests in middle age due to the slow progression of symptoms. Patients within this age range are more likely to seek medical attention and undergo treatment, leading to higher demand for therapeutic options. This segment benefits from increased healthcare utilization, more comprehensive treatment plans, and greater healthcare provider focus. The significant prevalence of acromegaly among individuals in this age bracket drives substantial market revenue and establishes it as the leading segment in terms of market share.

The age group segment of 61 and above is experiencing the fastest growth in the Acromegaly Therapeutics Market. This rise is driven by the increasing life expectancy and the growing population of elderly individuals, who are now more frequently diagnosed with acromegaly. The market for this segment is expanding due to advancements in diagnostic technologies that facilitate earlier detection and the development of tailored therapies suited for older patients. Enhanced healthcare services and an increased focus on managing chronic conditions in elderly populations contribute to the rapid growth of this segment. As the elderly population continues to expand, demand for effective acromegaly treatments is expected to surge, driving substantial market growth.

• Less than 40
• 41-60
• 6l above

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Bio :

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over three years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies.

In her current role, Manjiri handles the market research related to Pharma and healthcare industry. Her passion lies in utilizing innovative approaches to distill complex information into strategic insights that empower organizations to make informed decisions.Manjiri remains an invaluable asset in the dynamic landscape of market research.

Read More




Author's Conclusion

Conclusion

• The global Acromegaly Therapeutics Market will expand significantly by 6.00% CAGR between 2024 and 2031.
• The dominant category in the Type segment is somatostatin analogs due to their established efficacy in managing growth hormone levels in acromegaly patients.
• In the Age Group segment, the 41-60 years category leads because it encompasses the majority of diagnosed cases, reflecting the typical age of onset for acromegaly.

Frequently Asked Questions (FAQs)

What is the market size for the Acromegaly Therapeutics Market in 2024?

The global market size for Acromegaly Therapeutics in 2024 is USD 2515.2 million.

What is the growth rate for the Acromegaly Therapeutics Market over the forecast period?

The global Acromegaly Therapeutics Market is expected to grow with a CAGR of 6.00% over the projected period.

Which is the leading region of the market for Acromegaly Therapeutics?

North America held a significant global Acromegaly Therapeutics Market revenue share in 2024.

Which region is projected to detect the fastest growth in the Acromegaly Therapeutics Market over the forecast period?

Asia-Pacific will witness the fastest growth of the global Acromegaly Therapeutics Market over the coming years.

Which country will be leading in the Acromegaly Therapeutics Market in 2024?

The US had the most significant global Acromegaly Therapeutics Market revenue share in 2024.

What are the key drivers for the growth of the Acromegaly Therapeutics Market?

Rising disease prevalence, advancements in diagnostic technology, and increased pharmaceutical R&D investment are fueling the growth of the Acromegaly Therapeutics Market.

Which is the significant Acromegaly Therapeutics Market segment by type?

Somatostatin analogs are the significant segment by type in the Acromegaly Therapeutics Market due to their effectiveness in controlling growth hormone secretion.